Lower extremity artery disease (LEAD) is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people. On top of that, LEAD also represents a prominent marker of ...

Results from the largest real-world propensity-matched comparison to date show that radial-to-peripheral (R2P) access ...

Both the incidence and degree of bleeding events after peripheral revascularization match what’s seen for coronary revascularization and for lower-extremity amputation, new findings from the EUCLID ...

The treatment of patients with peripheral arterial disease has evolved tremendously since the early 1960s, when Charles Dotter first successfully revascularized a superficial femoral artery occlusion ...

Patients with PAD who meet criteria for frailty can reap similar benefits as their nonfrail counterparts when prescribed a combination of low-dose direct oral anticoagulant and aspirin following lower ...

Patients with acute heart failure often require immediate treatment to restore optimal heart function. The 2 primary methods of revascularization are coronary artery bypass graft and percutaneous ...

Please provide your email address to receive an email when new articles are posted on . Rivaroxaban plus low-dose aspirin reduced incidence of total severe CV and other adverse events in patients with ...

Please provide your email address to receive an email when new articles are posted on . Symvess is a sterile, cell-free tissue engineered vessel made of human extracellular matrix proteins. Among 54 ...

DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...